{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:29:17Z","timestamp":1793968157927,"version":"4.8.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymthe.2025.03.062","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:30:23Z","timestamp":1743636623000},"page":"2192-2204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Four decades of adenovirus gene transfer vectors: History and current use"],"prefix":"10.1016","volume":"33","author":[{"given":"Neil R.","family":"Hackett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-6839","authenticated-orcid":false,"given":"Ronald G.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.062_bib1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/hum.2004.15.1167","article-title":"Adenovirus structure","volume":"15","author":"Rux","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2004.15.1022","article-title":"Biology of adenovirus and its use as a vector for gene therapy","volume":"15","author":"McConnell","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/v13122502","article-title":"Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy","volume":"13","author":"Watanabe","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.062_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0167-7799(90)90144-M","article-title":"Adenoviruses as expression vectors and recombinant vaccines","volume":"8","author":"Graham","year":"1990","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib5","first-page":"363","article-title":"Adenovirus-based expression vectors and recombinant vaccines","volume":"20","author":"Graham","year":"1992","journal-title":"Biotechnology"},{"key":"10.1016\/j.ymthe.2025.03.062_bib6","article-title":"Human adenoviruses: propagation, purification, quantification, and storage","volume":"14","author":"Green","year":"2006","journal-title":"Curr. Protoc. Microbiol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1099\/0022-1317-70-2-429","article-title":"Use of human adenovirus-based vectors for antigen expression in animals","volume":"70","author":"Prevec","year":"1989","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib8","first-page":"568","article-title":"Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys","volume":"4","author":"Prevec","year":"1991","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ymthe.2025.03.062_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.2017680","article-title":"Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in\u00a0vivo","volume":"252","author":"Rosenfeld","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.062_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-1-0716-0795-4_18","article-title":"Surface Modification of Adenovirus Vector to Improve Immunogenicity and Tropism","volume":"2183","author":"Gabal","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1089\/hum.2017.139","article-title":"Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector-Host Interactions for Therapy","volume":"28","author":"Hagedorn","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-62703-679-5_3","article-title":"Capsid modification strategies for detargeting adenoviral vectors","volume":"1089","author":"Parker","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1749-6632.1994.tb21705.x","article-title":"Adenovirus-mediated in\u00a0vivo gene transfer","volume":"716","author":"Brody","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.03.062_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymeth.2003.11.006","article-title":"Utilization of adenovirus vectors for multiple gene transfer applications","volume":"33","author":"Amalfitano","year":"2004","journal-title":"Methods"},{"key":"10.1016\/j.ymthe.2025.03.062_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/v15122378","article-title":"Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines","volume":"15","author":"Trivedi","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.062_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/v16071094","article-title":"Clinical Application of Adenovirus (AdV): A Comprehensive Review","volume":"16","author":"Salauddin","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.062_bib17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1172\/JCI7935","article-title":"Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus","volume":"104","author":"Harvey","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.062_bib18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.gt.3302809","article-title":"Gene therapy progress and prospects: cystic fibrosis","volume":"13","author":"Griesenbach","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.03.062_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","article-title":"Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial","volume":"28","author":"Somanathan","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ymthe.2025.03.062_bib22","doi-asserted-by":"crossref","first-page":"15265","DOI":"10.1128\/JVI.79.24.15265-15276.2005","article-title":"Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy","volume":"79","author":"Madisch","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/jmv.24749","article-title":"First isolation of a new type of human adenovirus (genotype 79), species Human mastadenovirus B (B2) from sewage water in Japan","volume":"89","author":"Yoshitomi","year":"2017","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0041-1733802","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Types, and Approach to Treatment","volume":"42","author":"Lynch","year":"2021","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/v16060973","article-title":"The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies","volume":"16","author":"Wallace","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.062_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2025.03.062_bib27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.062_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1083\/jcb.127.1.257","article-title":"Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization","volume":"127","author":"Wickham","year":"1994","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.addr.2007.06.007","article-title":"Intracellular trafficking of adenovirus: many means to many ends","volume":"59","author":"Leopold","year":"2007","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.03.062_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coviro.2021.03.006","article-title":"Adenovirus - a blueprint for gene delivery","volume":"48","author":"Greber","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41434-021-00278-2","article-title":"Characterization of integration frequency and insertion sites of adenovirus DNA into mouse liver genomic DNA following intravenous injection","volume":"29","author":"Wang","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/156652308784746440","article-title":"Episomal vectors for gene therapy","volume":"8","author":"Ehrhardt","year":"2008","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910522","article-title":"Concepts in Oncolytic Adenovirus Therapy","volume":"22","author":"Mantwill","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.062_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/viro.1997.8597","article-title":"Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line","volume":"233","author":"Louis","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.062_bib36","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"Bett","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/gt.2014.124","article-title":"Preferable sites and orientations of transgene inserted in the adenovirus vector genome: The E3 site may be unfavorable for transgene position","volume":"22","author":"Suzuki","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib38","first-page":"195","article-title":"Adenovirus","volume":"343","author":"Smith","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0169-409X(00)00125-3","article-title":"Adenovirus-mediated gene transfer to liver","volume":"46","author":"Wilson","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.03.062_bib40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1073\/pnas.96.2.355","article-title":"Adenovirus-mediated regulable target gene expression in\u00a0vivo","volume":"96","author":"Burcin","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.062_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0764-4469(97)85001-9","article-title":"Expression from cardiomyocyte-specific promoter after adenovirus-mediated gene transfer in\u00a0vitro and in\u00a0vivo","volume":"320","author":"Griscelli","year":"1997","journal-title":"C.\u00a0R. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.03.062_bib42","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V92.3.822","article-title":"Intermittent, repetitive corticosteroid-induced upregulation of platelet levels after adenovirus-mediated transfer to the liver of a chimeric glucocorticoid-responsive promoter controlling the thrombopoietin cDNA","volume":"92","author":"Narumi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.062_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib44","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","article-title":"Production of first generation adenovirus vectors: a review","volume":"7","author":"Danthinne","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib45","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1002\/jgm.503","article-title":"Development and optimization of an adenovirus production process","volume":"6","author":"Kamen","year":"2004","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib46","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1089\/hum.1994.5.12-1485","article-title":"Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1\u00a0+ delta E3) during multiple passages in 293 cells","volume":"5","author":"Lochm\u00fcller","year":"1994","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib47","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses","volume":"9","author":"Fallaux","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib48","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.gt.3302611","article-title":"Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications","volume":"12","author":"Burova","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib49","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/jvi.69.4.2004-2015.1995","article-title":"Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses","volume":"69","author":"Yang","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib50","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1128\/jvi.70.10.7209-7212.1996","article-title":"Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs","volume":"70","author":"Yang","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-2478(97)00049-7","article-title":"Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response","volume":"57","author":"Christ","year":"1997","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2025.03.062_bib53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ng0994-42","article-title":"Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis","volume":"8","author":"Crystal","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.03.062_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ng1095-191","article-title":"Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration","volume":"11","author":"Kay","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.03.062_bib55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1006\/bbrc.1995.2169","article-title":"Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice","volume":"213","author":"Lochm\u00fcller","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2025.03.062_bib56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","article-title":"Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency","volume":"96","author":"Wilson","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.03.062_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","article-title":"Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications","volume":"132","author":"Hartman","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.ymthe.2025.03.062_bib58","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/fvl.11.6","article-title":"Implications of the innate immune response to adenovirus and adenoviral vectors","volume":"6","author":"Gregory","year":"2011","journal-title":"Future Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ymthe.2006.03.024","article-title":"Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system","volume":"14","author":"Kiang","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib62","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/eji.1830251239","article-title":"Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector","volume":"25","author":"Juillard","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib63","doi-asserted-by":"crossref","first-page":"8934","DOI":"10.1128\/jvi.70.12.8934-8943.1996","article-title":"Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy","volume":"70","author":"Gao","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib64","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/jvi.70.9.6497-6501.1996","article-title":"A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4","volume":"70","author":"Brough","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib65","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/mthe.2001.0264","article-title":"Generation and characterization of E1\/E2a\/E3\/E4-deficient adenoviral vectors encoding human factor VIII","volume":"3","author":"Andrews","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib66","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.gt.3300825","article-title":"Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in\u00a0vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement","volume":"6","author":"Ji","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib67","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1073\/pnas.91.13.6196","article-title":"Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver","volume":"91","author":"Engelhardt","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.062_bib68","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","article-title":"A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal","volume":"93","author":"Parks","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.062_bib69","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib70","first-page":"1","article-title":"No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib71","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib72","first-page":"750","article-title":"Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs","volume":"2","author":"Wickham","year":"1995","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib73","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1172\/JCI5309","article-title":"CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts","volume":"103","author":"Hidaka","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.062_bib74","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nbt1196-1570","article-title":"Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types","volume":"14","author":"Wickham","year":"1996","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib75","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.gt.3303007","article-title":"Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob","volume":"14","author":"Miura","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib76","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/6185","article-title":"Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody","volume":"17","author":"Bartlett","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/v13071300","article-title":"Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions","volume":"13","author":"Weklak","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.062_bib78","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-defective vector based on a chimpanzee adenovirus","volume":"75","author":"Farina","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jgm.1530","article-title":"Creation of a panel of vectors based on ape adenovirus isolates","volume":"13","author":"Roy","year":"2011","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.062_bib81","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/10430340152712638","article-title":"Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions","volume":"13","author":"Harvey","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib82","first-page":"47","article-title":"COVID-19 vaccine-induced immune thrombotic thrombocytopenia: pathophysiology and diagnosis","volume":"104","author":"Dorgalaleh","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendon\u00e7a","year":"2021","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2025.03.062_bib84","article-title":"Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status","volume":"11","author":"Chavda","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.062_bib85","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.062_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"Plos Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib87","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1073\/pnas.84.13.4626","article-title":"Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters","volume":"84","author":"Morin","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.062_bib88","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0042-6822(89)90064-0","article-title":"Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B","volume":"169","author":"McDermott","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.062_bib89","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1099\/0022-1317-71-10-2425","article-title":"Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine","volume":"71","author":"Eloit","year":"1990","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib90","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1473-3099(24)00419-5","article-title":"Effectiveness of rVSV-ZEBOV vaccination during the 2018-20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study","volume":"24","author":"Meakin","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.062_bib91","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/mt.2008.141","article-title":"The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens","volume":"16","author":"Schirmbeck","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050447","article-title":"Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection","volume":"7","author":"Betts","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.062_bib93","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1128\/IAI.73.10.6885-6891.2005","article-title":"Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity","volume":"73","author":"Hashimoto","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2025.03.062_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq6364","article-title":"A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates","volume":"14","author":"Hunegnaw","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib95","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1086\/507644","article-title":"Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen","volume":"194","author":"Chiuchiolo","year":"2006","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.062_bib96","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","article-title":"Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial","volume":"401","author":"Hamer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.062_bib97","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","article-title":"Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial","volume":"23","author":"Mwesigwa","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.062_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106569","article-title":"Controversy surrounding the Sputnik V vaccine","volume":"187","author":"Cazzola","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib99","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/14760584.2023.2242528","article-title":"A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov","volume":"22","author":"Wang","year":"2023","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2025.03.062_bib100","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib101","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1473-3099(24)00358-X","article-title":"Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo\/HVTN 705\/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"24","author":"Gray","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.062_bib102","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140794","article-title":"A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","volume":"131","author":"Matsuda","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.062_bib103","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","article-title":"Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial","volume":"3","author":"Bosaeed","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ymthe.2025.03.062_bib104","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121077","article-title":"Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial","volume":"3","author":"Kim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.062_bib105","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13336","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older","volume":"18","author":"Eto","year":"2024","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.ymthe.2025.03.062_bib106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/hum.2012.163","article-title":"Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity","volume":"24","author":"De","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib107","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/npp.2011.200","article-title":"Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects","volume":"37","author":"Wee","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ymthe.2025.03.062_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239780","article-title":"Cocaine vaccine dAd5GNE protects against moderate daily and high-dose \u201cbinge\u201d cocaine use","volume":"15","author":"Havlicek","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.062_bib109","first-page":"125","article-title":"Adenovirus Capsid-Based Anti-entanyl Vaccine Protects Against Fentanyl-Induced Cardio-Respiratory Depression","volume":"32","author":"Kaminsky","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib111","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ymthe.2025.03.062_bib112","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene Firadenovec: First Approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.03.062_bib113","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/18715206113139990309","article-title":"Adenoviral vectors for prodrug activation-based gene therapy for cancer","volume":"14","author":"Doloff","year":"2014","journal-title":"Anticancer. Agents Med. Chem."},{"key":"10.1016\/j.ymthe.2025.03.062_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291315","article-title":"A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma","volume":"18","author":"Nyati","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.062_bib115","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.062_bib116","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1089\/hum.1996.7.12-1465","article-title":"Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial","volume":"7","author":"Eck","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib117","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib118","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","article-title":"Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial","volume":"14","author":"Westphal","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib119","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1200\/JCO.2012.44.7516","article-title":"Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results","volume":"31","author":"Herman","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib120","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib121","first-page":"74","article-title":"Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib122","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/jnci\/90.24.1894","article-title":"Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens","volume":"90","author":"Rosenberg","year":"1998","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2025.03.062_bib123","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141912","article-title":"Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009","volume":"6","author":"Pellom","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.062_bib124","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1634\/theoncologist.2019-0608","article-title":"A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA\/MUC1\/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2025.03.062_bib125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.cgt.7700771","article-title":"Replication-selective oncolytic viruses in the treatment of cancer","volume":"12","author":"Everts","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib126","first-page":"37","article-title":"Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy","volume":"4","author":"Oosterhoff","year":"2004","journal-title":"J.\u00a0Exp. Ther. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib127","article-title":"Commentary on oncolytic viruses: past, present, and future","volume":"11","author":"Larson","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.062_bib128","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2025.03.062_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/v15040901","article-title":"Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer","volume":"15","author":"Gavrikova","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.062_bib130","article-title":"TS-2021, a third-generation oncolytic adenovirus that carried Ki67 promoter, TGF-\u03b22 5'UTR, and IL-15 against experimental glioblastoma","volume":"96","author":"Wang","year":"2024","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib131","article-title":"A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma","volume":"9","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.062_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101056","article-title":"Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN\u03b2 induces an anti-tumor immune response in high grade serous ovarian cancer","volume":"57","author":"Peters","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2025.03.062_bib133","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","article-title":"A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina","volume":"42","author":"Grines","year":"2003","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib134","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2007.06.010","article-title":"Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials","volume":"50","author":"Henry","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2025.03.062_bib135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/hum.2012.137","article-title":"Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease","volume":"24","author":"Rosengart","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib136","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000658-199910000-00002","article-title":"Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA","volume":"230","author":"Rosengart","year":"1999","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ymthe.2025.03.062_bib137","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ymthe.2005.03.031","article-title":"Alteration of splicing signals in a genomic\/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy","volume":"12","author":"Amano","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib138","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymthe.2003.09.014","article-title":"Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs","volume":"9","author":"Whitlock","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.062_bib139","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.124.014054","article-title":"Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial","volume":"17","author":"Nakamura","year":"2024","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ymthe.2025.03.062_bib140","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.123.012997","article-title":"EXACT Trial: Results of the Phase 1 Dose-Escalation Study","volume":"16","author":"Povsic","year":"2023","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ymthe.2025.03.062_bib141","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.03.062_bib142","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl9238","article-title":"In\u00a0vivo prime editing of a metabolic liver disease in mice","volume":"14","author":"B\u00f6ck","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.062_bib143","first-page":"2085","article-title":"In\u00a0vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:37:32Z","timestamp":1792687052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":143,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525001625002710"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.062","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Four decades of adenovirus gene transfer vectors: History and current use","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}